Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma

Toxicity Patterns With Immunomodulating Antibodies and Their Combinations

(2015) John B.A.G. Haanen et al.   SEMINARS IN ONCOLOGY

OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy

(2014) Yannick Bulliard et al.   IMMUNOLOGY AND CELL BIOLOGY

Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs

(2014) Lei Lu et al.   Journal of Translational Medicine

Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model

(2014) Zineb Belcaid et al.   PLoS One

Targeting 4-1BB Costimulation to the Tumor Stroma with Bispecific Aptamer Conjugates Enhances the Therapeutic Index of Tumor Immunotherapy

(2014) B. Schrand et al.   Cancer Immunology Research

Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model

(2014) S. Chen et al.   Cancer Immunology Research

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

(2013) S. F. Slovin et al.   ANNALS OF ONCOLOGY

Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas

(2013) Jing Zeng et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

(2013) Yannick Bulliard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

(2013) Tyler R. Simpson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

GITR Pathway Activation Abrogates Tumor Immune Suppression through Loss of Regulatory T-cell Lineage Stability

(2013) D. A. Schaer et al.   Cancer Immunology Research

An In Vivo Immunotherapy Screen of Costimulatory Molecules Identifies Fc-OX40L as a Potent Reagent for the Treatment of Established Murine Gliomas

(2012) K. A. Murphy et al.   CLINICAL CANCER RESEARCH

Modulation of GITR for cancer immunotherapy

(2012) David A Schaer et al.   CURRENT OPINION IN IMMUNOLOGY

Cancer Immunoediting in Malignant Glioma

(2012) Gavin P. Dunn et al.   NEUROSURGERY

Temozolomide and Other Potential Agents for the Treatment of Glioblastoma Multiforme

(2012) Daniel T. Nagasawa et al.   NEUROSURGERY CLINICS OF NORTH AMERICA

Science gone translational: the OX40 agonist story

(2011) Andrew D. Weinberg et al.   IMMUNOLOGICAL REVIEWS

Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy

(2010) David Coe et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

CD4+ T Cells Regulate Pulmonary Metastasis of Mammary Carcinomas by Enhancing Protumor Properties of Macrophages

(2009) David G. DeNardo et al.   CANCER CELL

Glucocorticoid-induced tumor necrosis factor receptor stimulation enhances the multifunctionality of adoptively transferred tumor antigen-specific CD8+T cells with tumor regression

(2009) Naoko Imai et al.   CANCER SCIENCE

Regulatory T Cell-Resistant CD8+ T Cells Induced by Glucocorticoid-Induced Tumor Necrosis Factor Receptor Signaling

(2008) H. Nishikawa et al.   CANCER RESEARCH

Immunogenic cancer cell death: a key-lock paradigm

(2008) Antoine Tesniere et al.   CURRENT OPINION IN IMMUNOLOGY

High-Resolution, Small Animal Radiation Research Platform With X-Ray Tomographic Guidance Capabilities

(2008) John Wong et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS